Relay Therapeutics, Inc.
NASDAQ:RLAYBiotechnology
Healthcare
$15.91 +2.63%
+$0.41 today
- Market cap
- $3.52B
- Beta
- 1.75
- P/E (TTM)
- -10.5
- EPS (TTM)
- -$1.52
52W Low $3.03High $17.47
Volume 1.88M
Average 3.70M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$235.46M
FY 2025 · Annual
Investing Cash Flow
$192.80M
FY 2025 · Annual
Financing Cash Flow
$1.60M
FY 2025 · Annual
-99.4% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (363.87M) | (290.51M) | (341.97M) | (337.71M) | (276.48M) |
| Depreciation & Amortization | 3.93M | 4.13M | 5.27M | 5.46M | 3.56M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 48.45M | 56.14M | 86.03M | 94.14M | 62.42M |
| Change in Working Capital | 97.34M | 11.25M | (32.46M) | 14.62M | (23.31M) |
| Accounts Receivables | 77.79M | 97K | 5.22M | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 930K | 1.99M | (2.39M) | 0 | (11.44M) |
| Other Working Capital | 18.62M | 9.16M | (35.28M) | 14.62M | (11.87M) |
| Other Non-Cash Items | 139.74M | (10.5M) | (17.19M) | (25.62M) | (1.65M) |
| Operating Cash Flow | (74.41M) | (229.49M) | (300.32M) | (249.11M) | (235.46M) |
| Capital Expenditures | (3.47M) | (9.06M) | (4.13M) | (2.02M) | (410K) |
| Acquisitions (Net) | (25.3M) | 179.68M | 0 | 0 | 0 |
| Purchases of Investments | (980.67M) | (535.42M) | (385.54M) | (650.63M) | (122.97M) |
| Sales of Investments | 529.92M | 355.74M | 647.3M | 611.56M | 316.18M |
| Other Investing Activities | 0 | (179.68M) | 0 | 0 | 0 |
| Investing Cash Flow | (479.51M) | (188.75M) | 257.63M | (41.08M) | 192.8M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 382.21M | 284.74M | 30.28M | 265.89M | 1.6M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.88M | 5.17M | 4.47M | 4.26M | 0 |
| Financing Cash Flow | 388.09M | 289.91M | 34.75M | 270.15M | 1.6M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (165.83M) | (128.33M) | (7.93M) | (20.04M) | (41.05M) |
| Free Cash Flow | (77.88M) | (238.55M) | (304.44M) | (251.13M) | (235.87M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$276.5M
+ D&A$3.6M
+ Stock-Based Comp$62.4M
+ Deferred Tax$0
- Working Capital-$23.3M
- Other Non-Cash-$1.6M
= Operating Cash Flow-$235.5M
- Capex-$410.0K
= Free Cash Flow-$235.9M
Analysis
FY2025 free cash flow is -$235.9M. FCF conversion is 85.3% of net income. Operating cash flow was -$235.5M, with capex of -$410.0K. The largest bridge item is Stock-Based Comp at $62.4M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 |
Does RLAY generate free cash flow?
Relay Therapeutics, Inc. (RLAY) generated -$235.87M of free cash flow in fiscal 2025.
How much operating cash flow does RLAY produce?
Operating cash flow was -$235.46M, before capital expenditures of $410,000.00.
Continue the stock analysis
Jump to another research area for this company.